Cardiol Therapeutics Inc.
CRDL
NASDAQ·Healthcare·Drug Manufacturers - Specialty & Generic·Mkt cap $253.6M
$2.20
▲ +1.85%
P/E
-9.80
Mkt Cap
$253.6M
52-Wk Range
$0.88–$2.28
52-Week Range
$0.88 - $2.28
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 109.5% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary CardiolRx anti-fibrotic and anti-inflammatory platform technology
- First-mover advantage in cardioprotective COVID-19 and myocarditis indications
- Multiple formulations and delivery mechanisms in development pipeline
- International clinical trial infrastructure and regulatory expertise
Bear Case
1 risk
- Low volatility (beta 0.5).
Growth
Stable outlook
Advancement of Phase II/III CardiolRx trials toward potential regulatory approval
Value
Deep value opportunity - significant discount to Large Cap Pharma peers
Momentum
Hot
+103.7% over 3m
Quality
Loss-making
Mixed fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying CRDL right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 12, 2026
AUG 12, 2026
Reported EPS of -$0.04 vs -$0.09 consensus (+55.6% surprise).
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+55.6%
Revenue trend · last 8Q
—
—
—
—
—
—
—
—
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$0
$0
$0
$0
$0
$0
$0
$0
Margins · last 8Q
No margin history available.
Wall Street consensus
2 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: B. Riley · Aug 26, 2026
vs Industry
How CRDL stacks vs Drug Manufacturers - Specialty & Generic
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related